Search clinical trials for: Janus Kinase

Total 8814 results

Incyte Corporation

Completed

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Graft-versus-host Disease (GVHD)

Belgium, Italy, Spain, Saudi Arabia, Turkey, United Kingdom, Germany, Greece, Canada, Austria, France, Israel, Netherlands, Sweden, Switzerland, Korea, Republic of, Bulgaria, Japan, Norway, Czechia, Russian Federation, Jordan, Hungary, Ind... and more
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (contRAst 3)

Arthritis, Rheumatoid

United States, Germany, Canada, Czechia, Poland, South Africa, Korea, Republic of, Spain, Japan, Argentina, Belgium, Hungary, United Kingdom, Italy, Lithuania
AbbVie

Completed

A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate (SELECT-EARLY)

Rheumatoid Arthritis

United States, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, K... and more
CTI BioPharma

Terminated

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

COVID-19 | COVID | COVID19

United States
AbbVie

Completed

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Rheumatoid Arthritis (RA)

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Czechia, Germany, Greece, Hungary, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Romania, Russian... and more
AbbVie

Completed

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs (SELECTSUNRISE)

Rheumatoid Arthritis

Japan
AbbVie

Active, not recruiting

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
AbbVie

Active, not recruiting

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis (SELECT-AXIS 2)

Spondyloarthritis

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Hungary, Israel, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Russian Federation, Slovakia, Spain, Taiwan, Turkey, Ukr... and more
AbbVie

Active, not recruiting

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

Crohn's Disease (CD)

United States, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Romania, Slovakia, Spain, United Kingdom
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE)

Rheumatoid Arthritis

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, ... and more
AbbVie

Completed

A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone (SELECT-NEXT)

Rheumatoid Arthritis

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Kazakhstan, Korea, Republic of, Latvia, Lithuan... and more
AstraZeneca

Completed

A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma

Asthma

United Kingdom
Abu Dhabi Stem Cells Center

Withdrawn

The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients (SYBRA)

Rheumatoid Arthritis

United Arab Emirates
Theravance Biopharma

Terminated

Efficacy and Safety of TD-1473 in Crohn's Disease (DIONE)

Crohn's Disease

United States, Bulgaria, France, Georgia, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Portugal, Romania, Serbia, South Africa, Spain, Ukraine, Australia, Austria, Croatia, New Zealand, Russian Federation, United...
AbbVie

Completed

A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis (SELECT-AXIS 1)

Ankylosing Spondylitis (AS)

United States, Australia, Belgium, Canada, Croatia, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Spain, Sweden, United Kingdom
Shanghai East Hospital

Active, not recruiting

A Study to Evaluate JAK Inhibitor Cream in EGFR-inhibitor-induced Skin Rash

Acneiform Eruptions

China
AbbVie

Completed

A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Rising Up)

Atopic Dermatitis

Japan
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation (REACH2)

Corticosteroid Refractory Acute Graft vs Host Disease

Germany, Japan, Saudi Arabia, Turkey, United Kingdom, Spain, Canada, Italy, Australia, Austria, France, Korea, Republic of, Hong Kong, Israel, Netherlands, Russian Federation, Denmark, Greece, Taiwan, Norway, Czechia, Bulgaria
Pfizer

Completed

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis (JADE MOA)

Atopic Dermatitis

United States, Canada
AbbVie

Completed

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs (SELECT-BEYOND)

Rheumatoid Arthritis

United States, Australia, Austria, Belgium, Canada, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Korea, Republic of, Latvia, New Zealand, Poland, Portugal, Puerto Rico, Russian Federation, Slovakia, ... and more
AbbVie

Completed

A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

Hidradenitis Suppurativa (HS)

United States, Canada, Japan, Puerto Rico
AbbVie

Active, not recruiting

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

Atopic Dermatitis

United States, Norway, Puerto Rico
National Cancer Institute (NCI)

Terminated

Ruxolitinib for Adult T-Cell Leukemia

Leukemia, Adult T-Cell | T Cell Leukemia, Adult | T Cell Leukemia, HTLV I Associated

United States
AbbVie

Completed

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies (U-EXCEL)

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
Theravance Biopharma

Terminated

Efficacy & Safety of TD-1473 in Ulcerative Colitis (RHEA)

Ulcerative Colitis (UC)

United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
Theravance Biopharma

Terminated

TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

Ulcerative Colitis (UC)

United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
Incyte Corporation

Completed

A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Hidradenitis Suppurativa

Canada, Denmark, Germany
Incyte Corporation

Completed

A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
AbbVie

Completed

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
Centre Hospitalier Annecy Genevois

Completed

Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis (Ruxo-EPO)

Myelofibrosis; Anemia
AbbVie

Completed

An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis (BALANCE-EXTEND)

Rheumatoid Arthritis

United States, Belgium, Bulgaria, Chile, Czechia, Hungary, Israel, Latvia, Mexico, New Zealand, Poland, Puerto Rico, Russian Federation, Slovakia, South Africa, Spain, Ukraine, United Kingdom
Pfizer

Completed

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Atopic Dermatitis

Spain, Taiwan, United States, Korea, Republic of, Poland, Canada, Australia, Hungary, Germany, Latvia, Finland, Chile, Bulgaria, Slovakia, Italy
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Ulcerative Colitis (UC)

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea,... and more
Incyte Corporation

Completed

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

MPN (Myeloproliferative Neoplasms)

United States, Netherlands, Austria
Vastra Gotaland Region

Active, not recruiting

Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients (NeuMRA)

Depression | Brain Diseases | Pain | Fatigue | Rheumatoid Arthritis | Cognitive Decline | Hand Rheumatism

Sweden
Incyte Corporation

Terminated

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Hematologic Malignancies

United States, Spain, France, Italy
AbbVie

Completed

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis (U-Accomplish)

Ulcerative Colitis (UC)

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Incyte Corporation

Terminated

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

COVID-19

United States, Russian Federation
Alimentiv Inc.
Alimentiv Translational Research Consortium

Terminated

Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis (PROPHETIC)

Ulcerative Colitis

Netherlands
Incyte Corporation

Completed

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Graft-versus-host Disease (GVHD)

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Terminated

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
AbbVie

Completed

A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)

Rheumatoid Arthritis (RA)

Brazil, China, Korea, Republic of
Pfizer

Completed

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Skin Diseases | Immune System Diseases | Hypersensitivity | Hypersensitivity, Immediate | Genetic Diseases, Inborn | Skin Diseases, Genetic | Dermatitis | Eczema | Skin Diseases, Eczematous | Dermatitis, Atopic

United States, Spain, Taiwan, Germany, Canada, China, Poland, Belgium, Serbia, Brazil, Russian Federation, Israel, Latvia, Italy, Romania, Mexico, Argentina, Bulgaria, Chile, Netherlands, Slovakia
Pfizer

Completed

Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis (OCTAVE)

Ulcerative Colitis

United States, Spain, Canada, Denmark, France, Australia, Belgium, Korea, Republic of, Hungary, Israel, Germany, Slovakia, Taiwan, Netherlands, Poland, New Zealand, United Kingdom, Japan, Austria, Estonia, Czechia, South Africa, Ukr... and more
AbbVie

Terminated

A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

Rheumatoid Arthritis (RA)

Belgium, Canada, Czechia, Hungary, Poland, Spain, United Kingdom
Geron Corporation

Completed

Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

Myelofibrosis

United States, France, Italy, United Kingdom, Belgium, Germany, Taiwan, Spain, Israel, Korea, Republic of, Canada
AbbVie

Completed

A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy

Rheumatoid Arthritis
Philipps University Marburg Medical Center

Completed

Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS (RuXoCoil)

COVID | ARDS, Human

Germany
Incyte Corporation

Completed

GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease

Graft-versus-host Disease (GVHD)

United States, Spain, Belgium, France, Italy, Korea, Republic of, Finland, United Kingdom, Germany, Israel, Switzerland, Austria, Australia, Czechia, Greece, New Zealand, Poland, Portugal, Taiwan
AbbVie

No longer available

Expanded Access to Upadacitinib

Atopic Dermatitis (AD)

Search clinical trials for: Janus Kinase

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations